Despite multiple refinements in drug-eluting stent (DES) technology and implantation techniques, percutaneous coronary intervention (PCI) with DES is complicated by the continuous accrual of clinical events due to thrombosis and in-stent restenosis (ISR). Drug-coated balloon (DCB) angioplasty offers advantages related to drug elution from the balloon surface and the absence of permanent struts, and it yields non-inferior clinical outcomes in patients with ISR and de novo small vessel disease1. Historically eluting paclitaxel, DCBs with newer antiproliferative drugs, including sirolimus, have been developed and tested for DCB PCI23. To date, large-scale evidence on safety and efficacy beyond 1 year after sirolimus-coated balloon (SCB) PCI is limited.
EASTBOURNE (ClinicalTrials.gov: NCT03085823) is a prospective, multicentre, investigator-driven cohort study evaluating the performance of the MagicTouch SCB (Concept Medical) for PCI in all-comer patients enrolled at 38 European and Asian centres between September 2016 and November 2020. The study design and 1-year results have been previously reported3. Briefly, real-world patients with any clinical indication for PCI with DCB, i.e., de novo small vessel disease and ISR, were included. Among the exclusion criteria...
Sign up for free!
Join us for free and access thousands of articles from EuroIntervention, as well as presentations, videos, cases from PCRonline.com
